Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Tokyo Liver Cancer Chemotherapy Study Group.
A Phase II study of co-administration of uracil and tegafur (UFT) was performed in 32 patients with unresectable hepatocellular carcinoma. A dose of 400 mg/m2/day of UFT was administered orally, three times a day, for more than 4 weeks. Of 26 patients evaluable for response, one (3.8%) showed a partial response of 9 months' duration. There were no complete responders. A dose-limiting toxicity was gastrointestinal tract disturbance. Six patients (18.8%) had to discontinue UFT treatment because of gastrointestinal toxicity. The clinical advantage of tegafur in the treatment of hepatocellular carcinoma was not enhanced by co-administration of uracil.
D000284:Administration, Oral; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D014498:Uracil / Q000008:administration & dosage* / Q000009:adverse effects
D004338:Drug Combinations; D005641:Tegafur; D014498:Uracil